强化降压对肾小管损伤的影响:ACCORD试验参与者发现
该研究对ACCORD-BP试验中529例参与者进行纵向分析,比较强化降压(收缩压<120mmHg)与标准降压(收缩压<140mmHg)对肾小管损伤标志物和eGFR的影响。结果发现强化降压组2年时eGFR较低9.2mL/min/1.73m2,但尿白蛋白肌酐比更低30%,且4种肾小管损伤/修复/炎症标志物水平未升高或更低,提示eGFR下降主要反映血流动力学改变而非肾小管损伤。
要点
- 强化降压组2年eGFR较标准组低9.2mL/min/1.73m2,但尿ACR低30%。
- 4种尿肾小管标志物在强化降压组未升高或更低,不支持肾小管损伤。
- eGFR下降幅度最大的参与者,尿IL-18和YKL-40下降更明显。
核心结论
- 在ACCORD-BP试验参与者中,强化降压与eGFR下降相关,但未增加肾小管损伤标志物水平,提示eGFR下降主要反映血流动力学改变。
研究设计与样本
- ACCORD-BP试验参与者的纵向分析,纳入529例子组参与者,其中强化降压组260例,标准降压组269例。
主要发现
- 强化降压组2年eGFR较标准降压组低9.2mL/min/1.73m2。
- 强化降压组2年尿ACR较标准降压组低30%。
- 强化降压组4种尿生物标志物(KIM-1、IL-18、YKL-40、MCP-1)水平不变或更低。
- 在发生CKD的亚组(n=77)中,强化降压组尿ACR和4种标志物均未升高,而标准降压组IL-18升高。
临床怎么用
- 强化降压导致的eGFR下降可能为血流动力学效应,不应因此误判为肾小管损伤而停用降压治疗。
局限性
- 基线晚期CKD参与者较少。
- 治疗组间比较并非仅由随机化产生的组间比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Random assignment to intensive blood pressure (BP) lowering (systolic BP<120mmHg) compared to a less intensive BP target (systolic BP<140mmHg) in the Action to Control Cardiovascular Risk in Diabetes BP (ACCORD-BP) trial resulted in a more rapid decline in estimated glomerular filtration rate (eGFR). Whether this reflects hemodynamic effects or intrinsic kidney damage is unknown. STUDY DESIGN: Longitudinal analysis of a subgroup of clinical trial participants. SETTINGS & PARTICIPANTS: A subgroup of 529 participants in ACCORD-BP. EXPOSURES: Urine biomarkers of tubular injury (kidney injury molecule 1, interleukin 18 [IL-18]), repair (human cartilage glycoprotein 39 [YKL-40]), and inflammation (monocyte chemoattractant protein 1) at baseline and year 2. OUTCOMES: Changes in eGFR from baseline to 2 years. ANALYTICAL APPROACH: We compared changes in biomarker levels and eGFRs across participants treated to an intensive versus less intensive BP goal using analysis of covariance. RESULTS: Of 529 participants, 260 had been randomly assigned to the intensive and 269 to the standard BP arm. Mean age was 62±6.5 years and eGFR was 90mL/min/1.73m2. Baseline clinical characteristics, eGFRs, urinary albumin-creatinine ratios (ACRs), and urinary biomarker levels were similar across BP treatment groups. Compared to less intensive BP treatment, eGFR was 9.2mL/min/1.73m2 lower in the intensive BP treatment group at year 2. Despite the eGFR reduction, within this treatment group, ACR was 30% lower and 4 urinary biomarker levels were unchanged or lower at year 2. Also within this group, participants with the largest declines in eGFRs had greater reductions in urinary IL-18 and YKL-40 levels. In a subgroup analysis of participants developing incident chronic kidney disease (sustained 30% decline and eGFR<60mL/min/1.73m2; n=77), neither ACR nor 4 biomarker levels increased in the intensive treatment group, whereas the level of 1 biomarker, IL-18, increased in the less intensive treatment group. LIMITATIONS: Few participants with advanced baseline chronic kidney disease. Comparisons across treatment groups do not represent comparisons of treatment arms created solely through randomization. CONCLUSIONS: Among a subset of ACCORD-BP trial participants, intensive BP control was associated with reductions in eGFRs, but not with an increase in injury marker levels. These findings support that eGFR decline observed with intensive BP goals in ACCORD participants may predominantly reflect hemodynamic alterations.
引用
- Nadkarni GN, Chauhan K, Rao V, et al. Effect of Intensive Blood Pressure Lowering on Kidney Tubule Injury: Findings From the ACCORD Trial Study Participants. Am J Kidney Dis. 2018. PMID: 30291011. doi:10.1053/j.ajkd.2018.07.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。